Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:37 PM
Ignite Modification Date:
2025-12-24 @ 4:37 PM
NCT ID:
NCT01516866
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed adenocarcinoma of the prostate
* Identifiable prostate cancer-related bone metastases on bone scan in the spine, pelvis or other bone
* Patients must be starting a microtubule directed chemotherapy regimen for metastatic castrate-resistant prostate cancer OR
* Patients must be starting a AR-directed regimen (e.g. Abiraterone, MDV-3100, TAK-700, etc) for treatment of metastatic castrate-resistant prostate
Exclusion Criteria:
* Concurrent treatment with any other agent that is being used with the expressed purpose of treating of prostate cancer outside of the planned treatment regimen
* Patients who have received radiotherapy less than 4 weeks prior to registration.
* Patients who have received prior Strontium-89, Samarium-153, or other radioisotope.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sodium fluoride F-18 (NaF).
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Study:
NCT01516866
Study Brief:
Protocol Section:
NCT01516866